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CASE REPORT 
Cardiovascular and hormonal responses 
to electroconvulsive therapy 
Modification of an exaggerated response in an hypertensive patient by p-receptor blockade 
RONALD M. JONES AND PAUL R. KNIGHT 
Summary 
A patient suffering from severe psychiatric depression underwent a course of electroconvulsive therapy. A 
marked rise in systemic arterial pressure, heart rate and plasma catecholamines in response to 
electroconvulsive therapy was attenuated by /&receptor blockade using propranolol. The significance and 
mechanism of this attenuation are discussed. 
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A 74-year-old woman with severe depression was 
scheduled for a course of electroconvulsive ther- 
apy (ECT). The patient had mild to moderate 
hypertension (arterial blood pressure in the 
140/9&170/ 100 mmHg range), and was taking 
chlorthalidone 50 mg daily and oral potassium 
supplements. Although there was no indication of 
ischaemic heart disease, carotid and femoral 
artery bruits indicated that some degree of per- 
ipheral vascular disease was present. The electro- 
cardiogram demonstrated occasional premature 
atrial beats, but no ST segment or T-wave 
changes. The patient was given oxygen for 5 
minutes before induction of anaesthesia with 
methohexitone, 50 mg, intravenously. Muscle 
relaxation was achieved with suxamethonium 30 
mg, intravenously. The electrocardiogram was 
monitored throughout the procedure. Arterial 
blood pressure and heart rate were measured 
after atropine premedication but before induc- 
tion of anaesthesia (control), 30 seconds after 
methohexitone administration, 30 seconds after 
suxamethonium administration, and 15, 30, 60, 
90, 120, 180, 300 and 600 seconds after the 
application of ECT (130 volts for 0.75 seconds) 
(Table 1). Venous blood was taken for the 
measurement of plasma catecholamines (adrena- 
line, noradrenaline and dopamine), and plasma 
renin activity, before induction of anaesthesia 
(control) and 60 and 600 seconds after the 
application of ECT (Table 2). The tables sum- 
marise the cardiovascular and hormonal re- 
sponses, after different ECT, with and without 
8-adrenergic receptor blockade. b-blockade was 
achieved with propranolol, in 0.5 mg increments, 
given intravenously before induction of anaes- 
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Table 1. Haemodynamic response with and without 8-receptor blockade 
8-Blockade (propranolol 3 mg 
intravenously) No fi-blockade 
Blood pressure Heart rate Blood pressure Heart rate 
(mmHg) (beatslmin) RPP (mmHg) (beatslmin) RPP 
Control 14/70 98 13,720 130180 88 1 1,400 
30 Seconds after 
methohexitone 50 mg 
30 Seconds after 
suxamethonium 
50 mg 
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RPP= Rate Pressure Product (Systolic arterial pressure x heart rate). 
thesia, a total of 3 mg reducing the resting heart 
rate by 10 beats/minute. Cardiovascular and 
hormonal control values were in the absence of 
/3-receptor blockade. 
During ECT, in the absence of 8-receptor 
blockade, the rate pressure product (RPP = systo- 
lic arterial pressure x heart rate) reached 35 000 
and there was electrocardiographic evidence of 
myocardial ischaemia, as evidenced by S-T seg- 
ment depression, which persisted for approxima- 
tely 180 seconds, the S-T segments returning to 
the iso-electric line when the rate pressure pro- 
duct (RPP) had returned to less than 20 000. This 
was associated with an approximately fifteen-fold 
increase in plasma adrenaline and approximately 
three-fold increase in plasma noradrenaline. 
After j3-receptor blockade the peak RPP reached 
16000 associated with an increase in plasma 
adrenaline of approximately 7.5-fold whilst 
plasma noradrenaline increased only slightly. 
Adrenaline, noradrenaline and dopamine 
levels were determined by the radio-enzymatic 
method of Peuler & Johnson.' Plasma renin 
activity was determined by radio-immunoassay, 
using a commercially available kit (RIA-New 
England Nuclear, Medical Diagnostics Division, 
North Billerica, Massachusetts 01 862, USA). 
Discussion 
Cardiovascular complications are the main cause 
of mortality during ECT modified with barbitu- 
rates and muscle relaxants (drug modified ECT).2 
Twenty years ago, Griswold3 demonstrated that 
ECT stimulated the sympathetic nervous system 
causing a rise in plasma catecholamines that 
could be attenuated by intravenous barbiturates. 
Subsequent experiments in animals4 demon- 
strated that high spinal analgesia, in which the 
sympathetic outflow was blocked, also inhibited 
the increase in catecholamines as well as the 
increase in arterial blood pressure and heart rate. 
In these animal experiments, a dose-response 
relationship was demonstrated between the 
duration and strength of the current applied and 
the autonomic stimulation and cardiovascular 
response. Another study, in humans, using 120 V 
lasting 06-0.8 seconds, demonstrated a rise in 
mean arterial pressure of 40 mmHg after drug- 
modified ECT, associated with an approximately 
three-fold increase in plasma adrenaline and 
n~radrenaline.~ However, a rise of 100 mmHg in 
systolic arterial pressure was observed in one 
patient in this study, which was associated with a 
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fold increase in plasma noradrenaline. The blood 
for these catecholamine estimations was drawn 
30-60 seconds after ECT. In an early study using 
unmodified ECT of 5 seconds duration, the 
increase in plasma adrenaline was less than 
ten-fold and approximately two-fold for plasma 
n~radrenaline.~ 
In the case described, methohexitone and suxa- 
methonium were used to modify ECT. Blood 
pressure rose from a pre-induction value of 
130/80 to 250/140 mmHg and heart rate increased 
from 88 to 140 beats/minute. This represents an 
increase in RPP from I I 400 to 35 000. In com- 
mon with previous reports4s5 the maximal in- 
creases in arterial blood pressure and pulse rate 
occurred approximately 60 seconds after ECT 
and were returning toward control values after 10 
minutes. The maximal changes in blood pressure 
and heart rate corresponded to approximately a 
fifteen-fold increase in plasma adrenaline and a 
3-fold increase in plasma noradrenaline. 
Although the plasma adrenaline level approached 
the control value 10 minutes after ECT the 
noradrenaline level remained approximately 
twice that of control. These increases are con- 
siderably greater than reported in previous stu- 
 die^.^,^ Current methods of measuring plasma 
catecholamines, using the radio-immunoassay 
technique such as that of Peuler & Johnson’ are 
more accurate than earlier chemical methods of 
measurement, such as the method of Anton & 
Sayre6 used by Gravenstein et al.’ This may 
account for the discrepancy in the cardiovascular 
responses and catecholamine levels reported by 
the earlier investigators. It must be emphasised, 
however, that this is a single case report of a 
patient in whom a particularly striking increase in 
blood pressure and heart rate occurred in re- 
sponse to ECT. Experiments in man7 and ani- 
m a l ~ ~  have demonstrated, however, that at least a 
five-fold increase in circulating catecholamines is 
required to produce a significant cardiovascular 
response. The fifteen-fold increase in plasma 
adrenaline demonstrated in this report would 
certainly be sufficient to increase blood pressure 
and heart rate in this patient. 
After 8-adrenergic receptor blockade, using 
propranolol, the increases in blood pressure and 
heart rate were greatly attenuated, the RPP of 
16000 comparing to a RPP of 35000 without 
8-receptor blockade. This was associated with an 
attenuation of catecholamine release. It is diffi- 
cult to be certain of the precise mechanism for the 
attenuation of catecholamine release in the case 
reported, though a number of possibilities exist. It 
is known that fi-receptor agonists increase the 
release of noradrenaline from adrenergic nerve 
terminals* and that propranolol blocks this effect. 
Therefore, impairment of the release of norad- 
renaline following sympathetic stimulation might 
contribute to the antihypertensive effect. There is 
also a close relationship between the sympathetic 
nervous system and the renin-angiotensin sys- 
tem, and stimulation of one system enhances the 
activity of the ~ t h e r . ~ . l ~  Renin is stored in the 
granules of the juxtaglomerular cells of the 
afferent arteriolar wall and its release is inhibited 
by an increase in blood pressure and proprano- 
101.~’ Inhibition of renin release, after 8-receptor 
blockade, could therefore modify the stimulation 
of the sympathetic nervous system. Blockade of 
8-receptors may thus attenuate the cardiovascu- 
lar response to ECT by a number of interrelated 
mechanisms. Firstly, block of cardiac 8-receptors 
will modify the increase in blood pressure and 
heart rate caused by increased circulating cate- 
cholamines. Secondly, block of renin release by 
propranolol may modify the activation of the 
sympathetic nervous system. Thirdly, proprano- 
lo1 may attenuate the release of noradrenaline 
from adrenergic nerve terminals following sym- 
pathetic stimulation. 
We conclude that ECT even when modified by 
barbiturates and muscle relaxants may cause 
brief, intense stimulation of the sympathetic 
nervous system. The cardiovascular and hor- 
monal consequences of this stimulation may be 
modified by fi-adrenergic receptor blockade using 
propranolol. This is of particular importance in 
hypertensive patients and, in particular, those 
with ischaemic heart disease. 
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